List of Antibodies Companies in Canada - 45

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options. Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation. Come join us and be a part of the ground-breaking team set to unlock the power of targeted radiotherapy!

Ability Biologics is dedicated to developing innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases. The company utilizes its powerful AbiLeap™ discovery engine, which combines massively parallel, continuously learning AI with advanced cell targeting technology, to develop the most potent and selective antibody therapeutics for areas of great unmet need.

Affinity Biologicals Inc. is a biotechnology company based in Ancaster, Ontario, Canada, specializing in hemostasis diagnostics and research. Founded in 1987, the company develops, manufactures, and markets over 250 high-quality reagents and kits used in coagulation and thrombosis studies. Their product offerings include coagulation-related antibodies, matched-pair antibody sets for ELISA, depleted/deficient plasmas, and a line of complete ELISA kits. The company also provides tailored services such as research and development, custom manufacturing, and contract services to support clients in the biotechnology and healthcare sectors. Affinity Biologicals maintains a strong commitment to quality, operating under an ISO 13485:2003 registered Quality System and holding licenses from regulatory authorities like the US FDA and Health Canada. With a dedicated team of around 30 employees, Affinity Biologicals serves a global market through a network of distributors.

AGADA Biosciences is a biotechnology company that specializes in providing expert assistance with drug development programs in neuromuscular disease, offering pre-clinical trials in mouse models and human clinical trial support.

Privately-held Montreal-based biotechnology company Engaged in the discovery and development of therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. Currently having one clinical-stage program with phase I data. Portfolio of highly-specific, novel and clinically-relevant targets using the proprietary STAR technology. Exploiting a powerful a proprietary target discovery technology with the potential to expand pipeline. Established strategic partnerships to access mAb generation, humanization, antibody-drug conjugates, and CHO production technologies

Amplitude Ventures is a capital catalyst for highly innovative companies at the point of value acceleration. We work with Canada's most promising healthcare companies that share our vision of bringing groundbreaking technologies to patients. Amplitude is focused on building world-class Canadian companies in precision medicine and next-generation medical devices. Since 2012, the Amplitude team has deployed a venture growth model used to build Canadian companies with world-class management teams and scale companies to breakout potential. This model has been used by the team to create, build, and grow companies, resulting in over $1 billion in company value. Our offices are in Montreal, Toronto, and Vancouver.

Anogen-Yes Biotech Laboratories Ltd. is a biotech company located in Mississauga, Canada. Founded in 1989, we have been a proud supplier of high quality antibody-based products for 30 years. We offer more than 300 monoclonal and polyclonal antibodies and more than 60 types of ELISA kits for research, diagnostic and therapeutic applications. As a research-focused company, we have also developed many a number of proprietary diagnostic and therapeutic products. Our product Abcream, an effective anti-IL-8 (CXCL8) monoclonal antibody topical treatment for psoriasis, had received approval by State Food & Drug Administration (SFDA) of China in 2001 and many international patents. Our neonatal TSH ELISA kit for diagnostic purposes has also been licensed by Health Canada. We also initiated research and developed products for inflammation, Alzheimer’s disease, and cancer. Learn more about our R&D projects under the “R&D Projects” tab. We have been ISO certified since 2000. We guarantee that every product delivered to our customers is of the best quality. With our in-house cell bank of more than 1000 hybridomas, we are able to monitor and control the entire manufacturing progress to ensure that our antibodies and ELISA kits are the best on the market. We provide antibodies, ELISA kits, and other lab reagents to major biotechnology and pharmaceutical companies, laboratories, hospitals, and academic and government research institutions around the world. We also work with distributors across the globe to make our product more accessible. At Anogen, we devote ourselves to produce high-quality and reliable antibody products for biomedical research, and hope that our contributions to the field can benefit patients, and improve the future of medicine.

Arch works closely with the scientific community, universities and research institutions to advance and build the value of select medical innovations, develop the most promising intellectual property, and create value for its investors. The company holds a strong patent portfolio of new drug candidates to prevent inflammation and organ injury. Arch’s Phase I and Phase II clinical trials led to LSALT peptide (Metablok), being the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial involving fifty-five hospitals across Canada. • Arch scientists described a novel mechanism of action for organ inflammation in the journal Cell. • Arch scientists identified the enzyme dipeptidase-1 (DPEP1) as a major neutrophil (white blood cell) adhesion receptor in the lungs, kidneys and liver. • DPEP1 was shown to be the target of LSALT peptide (Metablok), the Company’s lead drug candidate targeting inflammation in the lungs and kidneys. Arch is currently working to advance LSALT peptide through the production of additional human safety and efficacy data in a Phase II trial to prevent IRI-acute kidney injury (AKI). Please follow the company on LinkedIn, and subscribe at the website for the latest science and investor news.

BenchSci is a biotechnology company that offers an AI-powered platform to accelerate biomedical research by providing researchers with antibody search and selection tools.

Welcome to Biomatik - Your Quality Source of Integrated Products & Services for Life Sciences and Drug Discovery! ​Biomatik has been proudly serving the life sciences and drug discovery industry since 2002. In the first 10 years, Biomatik had been primarily focusing on Biochemicals, Gene Synthesis, and Peptide Synthesis. In the past 5 years, Biomatik has largely outgrown the above product lines and is rapidly expanding its new product lines: ELISA Kits, Proteins, and Antibodies. Offered Products: 22,000+ ELISA Kits, 26,000+ Antibodies, 15,000+ Proteins, 300+ Biochemicals Offered Services: Gene Synthesis, Peptide Synthesis, Protein Expression and Antibody Production Services To date, in addition to our catalog products, Biomatik has delivered 52,000+ custom-made products to our researchers worldwide. You can count on the quality products and tech support from Biomatik for your research needs. Please​ view our customer testimonials and some of the well-respected publications citing our fine products at Google Scholar​. Biomatik works closely with its partners at the R&D and production levels, along with 35+ distributors all over the world. Our goal is to provide worldwide researchers with high-quality research products and customized solutions at highly competitive prices - to be a truly valuable partner in unveiling the mysteries of the life sciences. We sincerely invite you to join our list of satisfied customers worldwide.

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies is licenced to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Cytodiagnostics is a biotechnology and diagnostics company based in Burlington, ON, Canada, and Tulsa, OK, USA, and a Research and Development Position at the Innovate Calgary Life Science Hub at the University of Calgary. Over the past fifteen years, Cytodiagnostics has become the pre-eminent global supplier of gold and silver nanoparticles. With a commitment to providing quality materials, our in-depth knowledge of particle behaviour spans from initial synthesis to chemical functionalization and detection molecule conjugation, giving us a unique advantage for incorporating nanoparticles into diagnostic tests. This realization led to the creation of CytoGROUP, a branch of our business with the mission of using excellent materials to provide top-notch lab-based and point-of-care diagnostics. Our team has applied their expertise with chemical modifications as well as antibody and cutting-edge nucleic acid/aptamer detection molecules to create a range of products from lateral flow tests to plate-based assays, along with custom diagnostic test development services. In addition to our two locations, Cytodiagnostics also has an associate company, CytoGroup, which specializes in lateral flow and vertical flow assays, ELISA, ELASA and Aptamer Development. Both products and development services are available. Our goal is to serve our customers with the highest quality products to ensure success in their research and development efforts.

Defence Therapeutics is a publicly-traded (CSE: DTC, OTCQB: DTCFF, FSE: DTC) clinical-stage biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.

At Eyam, our mission is to bring “Next Generation” vaccine and therapeutic technologies to market to solve today's health care needs.

On June 6, 2024, AstraZeneca announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most advanced programme, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), and brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca. It also strengthens AstraZeneca’s presence in and commitment to Canada. As a result of the acquisition, Fusion has become a wholly owned subsidiary of AstraZeneca, with operations in Canada and the US. At Fusion, we are pushing the boundaries of science to create innovative precision medicines for cancer. We are a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. We have developed our Targeted Alpha Therapies, or TAT, platform together with our proprietary Fast-Clear™ linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the therapies to tumors.

We are Gemina Labs, a point-of-care test developer with a proprietary breakthrough chemistry platform. Founded in 2020, the Gemina chemistry platform is an advanced, “universal” bio-sensing toolkit that enables a new generation of diagnostic tests for infectious diseases and beyond. The chemistry platform isn’t just high-performing. It also overcomes many supply chain accuracy bottlenecks in the sector and cuts the development time for prototype tests to weeks. Best of all, the platform empowers “quantitative testing” (not just positive/negative tests) that opens up new applications in personal well-being (stress, fatigue monitoring etc.)

We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47. DOS47 is our patented oncology platform technology that offers a new and revolutionary approach to the debilitation and destruction of cancer cells. Helix is led by an experienced Management team with excellent pharmaceutical development expertise and proven business skills. The group is committed in developing novel medicines through DOS47 platform technology.

Science has successfully shown that the human immune system can be enhanced by introducing immunoglobulin or Ig antibodies targeted toward specific pathogens. The highest concentration of compatible Ig is found in chicken hen eggs called IgY. Our proprietary ability to commercially produce IgY antibodies presents the breakthrough potential to solve some of the most important immune health challenges faced today. Our proprietary technology and process allows for the most cost-effective highest purity IgY protein antibodies globally available today with purity levels up to 95% . Our IgY is 100% natural with no harsh chemicals used in the extraction process, a low flavor, odor & color profile and is available in powder & liquid format making it attractive for a variety of applications including nutraceuticals such as general dietary daily supplements from infants to seniors, General foods & beverages, Sports nutrition supplements, Pet food & health products. There are also cosmeceutical, agricultural and pharmaceutical applications.

Immune Biosolutions is a clinical stage biotech company specializing in discovering and engineering avian and human antibodies for therapeutic and diagnostic applications. Our cutting-edge techniques, including phage display and single B cell screening technologies, enable us to engineer custom-fit immunotherapeutic agents. Our discovery platform is available for biotech and pharma partners, providing access to highly conserved mammalian lineage targets and opening up new possibilities for innovative therapeutics. Our biomanufacturing capacity, which has already supported successful internal clinical trials, is also available for partners in a fee-for-service model. Our internal pipeline includes several discovery programs for various cancer and infectious disease indications. Through our platform, we generate diverse antibodies with high binding affinity and novel paratopes, paving the way for exciting new approaches to treating difficult proteins.

ImmVue Therapeutics is a company that develops small-molecule screen KISMEHT to identify allosteric modulators of the kinase family. Its lead compounds use lymphocytes and aim to revert patients to their vibrant selves with innovative medicines that target novel mechanisms to revitalize their immune system.

We’re at the forefront of next-generation antibody drug conjugate discovery, thanks to our innovative, in-house developed Smart AntibodiesTM delivery technologies and utilization of the next-generation smart Payloads such as oligonucleotides, PROTAC, and peptides. Our mission? To unlock the vast therapeutic potential of the antibody drug conjugate modality. To achieve this, we’re engaged in expansive global collaborations with leaders in therapeutic research.

KisoJi is dedicated to developing multi-specific antibody technologies and therapeutics that improve outcomes in oncology.

Marea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing small molecules to address hypertriglyceridemia and other metabolic diseases.

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

ME Therapeutics is a Biotechnology company that specializes in Immuno Oncology, focusing on treating previously untreatable cancers by targeting the immune system.

Nicoya is a Canadian biotechnology company dedicated to improving human life by helping scientists succeed. Established in 2012, Nicoya was founded by Ryan Denomme in his relentless pursuit to use nanotechnology to increase the affordability and ease of use of scientific instruments. Within 10 years, Nicoya has grown to a team of 100+ employees who have extensive experience working at the forefront of nanotechnology and biotechnology sectors. Nicoya develops innovative and accessible biosensor technology for in-depth characterization of biomolecular interactions. Alto, the world's first digital high-throughput benchtop SPR instrument, is capable of accelerating drug discovery using a fraction of sample volume traditionally required for biomolecular interaction analyses. Alto helps biotechnology and pharmaceutical companies go-to-market faster with increased efficiency and success early in their product pipelines. Join us on our mission to improve human life by helping scientists to succeed. For job opportunities, see our webpage at https://nicoyalife.com/about/careers/

ATGen Canada/NKMax Canada is the Canadian division of NKMax Co Ltd (Korea), a public biotechnology company dedicated to restoring and enhancing overall immune integrity. NK Vue, NKMax’s proprietary blood test for the measurement of immune function, is the first commercially available test that quantifies natural killer cell activity in a small volume of stimulated whole blood. NKMax also develops its proprietary natural killer cell expansion and activation technology as a treatment for a number of cancers and other disorders, and is currently conducting clinical trials in the US and Korea.

Nomic (formerly nplex biosciences) is a bioengineering company working to make the human proteome as broadly and easily accessible as the human genome. We are building the nELISA, a next-generation ELISA platform for measuring proteins at scale and at high throughput. The nELISA was designed to seamlessly integrate into current workflows in biology and is uniquely adaptable to a wide variety of use cases within drug and biomarker development workflows. Nomic is headquartered in Montreal, with labs and offices in Boston. For more information, visit www.nomic.bio.

Pacylex Pharmaceuticals is a clinical stage company developing a first-in-class, daily, oral cancer therapy with a novel, broad, mechanism of action, as a refractory cancer monotherapy and potential future combination therapy. PCLX-001 is a small molecule, N-myristoylation inhibitor that selectively kills cultured human leukemia and lymphoma cells ex-vivo, completely shrinks leukemia and lymphoma tumors in mice including tumors from drug resistant patients, and strongly inhibits growth of solid tumors in mice including breast and certain lung cancers. In an ongoing Phase 1 clinical trial, PCLX-001 has excellent bioavailability, half-life, and drug exposure with an acceptable safety profile to date when administered orally once daily to patients with relapsed advanced solid tumors or refractory B-cell lymphomas. Since this Phase 1 dose escalation clinical study is nearing the target recommended Phase 2 dose (RP2D), Pacylex is planning to expand the clinical program to AML at MD Anderson this fall in a DoD-supported Phase 2 study, as well as start two Phase 2 studies in DLBCL and solid tumor patients.

Paradox Immunotherapeutics is an pharmaceutical company developing immunotherapies for rare diseases using a proven-successful immunotherapy drug design platform. We design drugs that harness the body’s own immune system to clear lethal deposits from affected organs and reverse organ damage. Our team has a successful history in designing drug candidates for amyloidosis and taking them from bench to bedside. Using the same platform technology, our lead candidate includes a potential treatment for immunoglobulin light chain (AL) cardiac amyloidosis. Their other discovery pipelines include treatments for chronic renal failure and neurodegenerative diseases. With a team of experts in immunotherapy drug design, they possess an orphan drug discovery platform, termed "The PARADOX Platform" for the potential treatment of ~30 rare diseases, a platform technology which has already sparked the interest of major players in the pharmaceutical industry.

Phenomic is an innovative biotech company based in Boston and Toronto that specializes in developing new medicines targeting the tumor stroma. The tumor stroma is a dense web of connective tissue that surrounds solid tumors and plays a crucial role in treatment resistance and disease progression. Phenomic's scTx platform contains an extensive and optimally-curated atlas of single-cell cancer and normal tissue data and is powered by proprietary machine learning software to provide unparalleled insight into target expression and selectivity. Using scTx, Phenomic can identify exquisitely selective targets that can directly reprogram the tumor microenvironment or deliver cancer-killing payloads such as immune engagers and antibody-drug conjugates. Additionally, Phenomic has developed tumor stroma-specific experimental systems, including co-culture and disease-relevant in vivo models, to dissect stromal biology and maximize the likelihood of clinical success. Phenomic's lead program targets a novel extracellular matrix protein identified by scTx that is highly tumor selective and expressed by a pathogenic subtype of cancer-associated fibroblasts we term ecmCAFs. We have demonstrated clear in vivo proof-of-concept for this program building our conviction in scTx’s ability to identify novel high-impact, druggable targets.

PlantForm Corporation is a Canadian biotech company with a low-cost, proprietary manufacturing platform for a wide range of plant-made pharmaceuticals, including monoclonal antibodies, therapeutic proteins and vaccines for the treatment of cancer, HIV/AIDS, Ebola virus and other life-threatening illnesses. The company’s vivoXPRESS® plant-based technology platform produces biopharmaceutical products in fully contained greenhouse environments. PlantForm’s pipeline features both innovator and biosimilar products, including: • 3 biosimilar cancer drugs, leading with trastuzumab, a plant-produced version of the breast cancer drug Herceptin® • innovator antibodies for HIV/AIDS, funded by the Government of Canada and the Bill & Melinda Gates Foundation • innovator antibodies for treatment of Ebola virus (Sudan strain), with financial support from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) and in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) • recombinant butyrylcholinesterase (BuChE), an enzyme used as preventative medicine for people vulnerable to attack by nerve agents, organophosphates or other stimulants. PlantForm is interested in establishing partnerships with other companies to develop additional targeted biosimilar and innovator drugs.

ProMIS Neurosciences, Inc. is a leading development-stage biotechnology company based in Toronto, Ontario and Cambridge, Massachusetts. The company is focused on the treatment of Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy through the development of antibody therapeutics and diagnostics. ProMIS Neurosciences is publicly traded on the Toronto Stock Exchange.

ProMIS Neurosciences is focused on the treatment of Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy through the discovery and development of antibodies selective for toxic misfolded proteins driving these diseases.

QurCan Therapeutics (formerly Nanology Labs Inc) is a biotechnology company using advanced nanoparticle drug-delivery technology to unleash the immense potential of next-generation biological and genetic medicine and deliver life-changing therapeutics. QurCan's next generation nanoparticle platform, TERP, enables tissue-selective delivery of nucleotides and biological therapeutics to extra-hepatic sites, including brain and spleen. TERP technology is a breakthrough technology with the great potential to deliver a new era of disease-modifying genetic medicine that will make a difference to patients with a wide range of unmet medical needs.

Radiant Biotherapeutics: Transformative, multi-valent, multi-specific antibody platform: Multabody Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. The proprietary Multabody platform leverages avidity and multi-specificity simultaneously, to generate highly efficacious Multabodies with superior potency than other antibody platforms. These powerful Multabodies have potential to deliver a new class of biologics to tackle complex, heterogenous diseases, such as cancer, that often have challenging targets and mechanisms. Multabody production and manufacturing is flexible, modular and scalable, and leverages standard antibody CMC processes. The groundbreaking efficiency of the platform is driving a novel pipeline of mono-, bi- and tri-specific biologics in multiple therapeutics areas. Strategic partnerships with two leading biopharmaceutical companies validate the platform and its broad scientific and clinical utility. For more, visit radiantbio.com.

Ranomics offers high throughput solutions for protein engineering, drug discovery, genomics research and synthetic biology. Using our VariantFind and VERG genomics platforms, Ranomics offers partners the a scalable solution to engineer and screen genetic variants in a wide range of model organisms. Our industry leading DNA Variant libraries and high-throughput cell assays help researchers to hit their research objectives faster and with better results than traditional methods. Over the years, we have worked with top biotech and pharma companies in the US and worldwide. Our partners have used our technologies to advance their R&D and drug discovery projects, and to publish papers in Nature Biotechnology, mAbs, and other journals.

Rapid Novor Inc. is the world's leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence antibody proteins without needing to access the producing cell line. As a University of Waterloo spin-off, the company is building its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company's REmAb™ antibody protein sequencing service has allowed for the accurate sequencing of any given antibody proteins on a routine basis. The company's WILD™ service is the first commercially available service that can accurately distinguish the isobaric Isoleucine and Leucine using mass spectrometry. The company's mission is to advance life science for better human health with next generation protein sequencing. For more information, visit www.rapidnovor.com. Follow the company on Twitter @rapidnovor.

SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.

Carisma Therapeutics Closes Merger with Sesen Bio (3/7/23) Shares of Carisma to commence trading on Nasdaq under new ticker symbol "CARM" We are passionate in our commitment to improving and renewing people's lives. Sesen Bio is a late-stage company developing fusion protein medicines for people with cancer. Our fusion protein approach tethers a tumor-targeting antibody fragment to a protein cytotoxic payload to form a single protein molecule designed to selectively and broadly kill cancer cells while sparing healthy cells and to activate the body’s innate immune response system. The most advanced program in our pipeline is Vicinium™, a novel investigational anti-cancer treatment that has the potential to treat multiple cancers driven by overexpression of EpCAM, such as non-muscle invasive bladder (NMIBC) and squamous cell carcinoma of the head and neck (SCCHN). We are currently advancing Vicinium in a Phase 3 registration trial for the treatment of people with NMIBC who have been previously treated with bacillus Calmette-Guérin (BCG), with positive three-month efficacy results established and 12-month study results expected in mid-2019. Due to Vicinium’s potential to promote an anti-tumor immune response, we believe it holds promise as a combination treatment with immuno-oncology drugs, such as checkpoint inhibitors. The first assessment of this is in a clinical study combing Vicinium with AstraZeneca’s durvalumab, in NMIBC. For more information, please visit www.sesenbio.com.

Somru BioScience is an emerging biotechnology company dedicated to developing breakthrough antibody technology for research, diagnostic and therapeutic applications.

STEMCELL Technologies is a Canadian biotechnology company that helps power leading-edge life science research around the world. Driven by our love of science and passion for quality, we are Scientists Helping Scientists—standing by our customers to provide the outstanding products, technical support, and training they need to advance their research. Scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research are among those who rely on our cell culture media, cell separation products, instruments, accessory products, and services. Since the launch of the company by Dr. Allen Eaves in 1993, STEMCELL has reinvested all profits back into the research and development of products to better support the international research community. Today, STEMCELL is the largest biotech company in Canada, with over 2000 employees globally, most with scientific or engineering degrees. Through our many regional offices, as well as our distribution centers in Vancouver, Seattle, Grenoble, and Singapore, we deliver our innovative, specialized products to more than 70 countries. At STEMCELL, we are dedicated to improving lives through advancing knowledge and scientific discovery, through our commitment to fostering diversity and inclusion in STEM and the life sciences industry, and through our investments in sustainability, community, and social responsibility. We do all this because we love science as much as you do. #ScientistsHelpingScientists

Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC). Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with investigational new drug applications for ZW220 and ZW251 planned for 2025.